David Silberstein, Ph.D.

Dr. Silberstein has served as a director since June 2018. Dr. Silberstein has served as a chief operating officer of BioMimetix Pharmaceutical, Inc. since 2013. Dr. Silberstein has served as a director of BMI since 2016. Dr. Silberstein received his Ph.D. in Immunology at Columbia University and Postdoctoral training at Harvard Medical School/Brigham & Women’s Hospital.

Dr. Silberstein continued for seven years at Harvard, leading a research team studying the biochemistry of inflammation. This was followed by 20 years at AstraZeneca Pharmaceuticals where Dr. Silberstein had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion.

Since 2013, Dr. Silberstein has worked independently with a number of early-stage biotech companies and as a consultant to investment firms. Current work includes his role as Principal Investigator of an NCI-funded clinical trial in patients with multiple brain metastases.